Gregory Lewis is a DPhil Scholar at the Future of Humanity Institute, where he investigates long-run impacts and potential catastrophic risk from advancing biotechnology. He is a D. Phil student in Michael Bonsall’s mathematical ecology group. Previously, he was an academic clinical fellow in public health medicine, where he won the O’Brien prize, and before that a junior doctor. He holds a master’s in public health (with distinction) and a medical degree, both from Cambridge University. Prior to reading medicine, he represented Great Britain in the international biology Olympiad.
Keynote
Philanthropy
Dr. Himanshu Brahmbhatt
EnGeneIC
He co-founded EnGeneIC
and built it from concept to a clinical stage biopharmaceutical company
(Sydney and New York). He is the principal inventor (435 granted patents
world-wide) of EnGeneIC Dream Vector cyto-immunotherapeutic technology for
treatment of several different cancers and for COVID-19. Himanshu is the
principal author on several high impact scientific and clinical research
papers. He has a strong background in R & D innovation and
biopharmaceuticals business. He graduated with a Ph.D (University of
Adelaide) and did post-doctoral research at the Geneva Medical Centre,
National Centre for Research in Biotechnology (Germany) and CSIRO
(Australia).
Keynote
Private Company
Healthcare, Biotech
Bradley Hardiman, David Peerless
Adrenaline Ventures
Bradley is an experienced healthcare investor, investing in early stage companies in sectors such as therapeutics, medical devices and digital health. He spent seven and a half years with the seed funds team at Cambridge Enterprise, creating and investing in companies spinning out of the University of Cambridge.
David has a financial services background with a focus on China and Hong Kong and a particular focus on healthcare. He has expertise in helping companies grow and ultimately IPO on public stock exchanges, including AIM, Hong Kong, New York and NASDAQ.
Keynote
Venture Capital
Biotech, EIS & VCT, Healthcare
Corporates
Company backgrounds and useful links.
Future of Humanity Institute
Gregory Lewis
The Future of Humanity Institute is a unique world-leading research centre that works on big picture questions for human civilisation and explores what can be done now to ensure a flourishing long-term future. Its multidisciplinary research team includes several of the world’s most brilliant and famous minds working in this area. Its work spans the disciplines of mathematics, philosophy, computer science, engineering, ethics, economics, and political science.
Keynote
Philanthropy
EnGeneIC
Dr. Himanshu Brahmbhatt
EnGeneIC is a clinical-stage biopharmaceutical company, developing an innovative cyto-immunotherapy nanomedicine focused on cancer and COVID-19 treatments.
EDV (EnGeneIC Dream Vector) technology has the potential to save the lives of vulnerable (elderly and/or immune-compromised) coronavirus infected patients by lifting the suppressed immune system and producing the key virus fighting molecules in a physiological manner. This would prevent the virus from taking over both lungs, causing respiratory distress and subsequent death. Lifting of the virus fighting immune system has been demonstrated in end-stage cancer patients and EnGeneIC has manufactured the human doses to progress into a clinical trial in coronavirus infected patients.
Keynote
Private Company
Healthcare, Biotech
Adrenaline Ventures
Bradley Hardiman, David Peerless
Adrenaline Capital Partners is an emerging fund manager, currently closing its maiden fund. The fund will invest in UK based, early technology companies operating in the field of data driven healthcare and engineering.
The team brings a wealth of experience of healthcare and engineering investment, along with scaling, growth and overseas expansion.
Adrenaline has an offer of investment of £60m of its £150m target and is working towards a first close. We are seeking additional Limited Partners to join the fund.
